Synergistic effect of lipopeptide biosurfactant with antibiotics against Escherichia coli CFT073 biofilm

International Journal of Antimicrobial Agents

Volumn 37, Issue 4, 2011, Pages 324-331

  Rivardo, Fabrizio ^a,b   Martinotti, Maria Giovanna ^a   Turner, Raymond Joseph ^b   Ceri, Howard ^b  

^a UNIVERSITY OF EASTERN PIEDMONT   (Italy)

^b UNIVERSITY OF CALGARY   (Canada)

Author keywords

Biofilm; Biosurfactant; Eradication; Lipopeptide; Synergy; Uropathogenic Escherichia coli

Indexed keywords

AMPICILLIN; BIOSURFACTANT; CEFAZOLIN; CEFTRIAXONE; CIPROFLOXACIN; COTRIMOXAZOLE; PIPERACILLIN; POLYSTYRENE; TOBRAMYCIN;

ARTICLE; BACILLUS LICHENIFORMIS; BACTERICIDAL ACTIVITY; BACTERIUM ADHERENCE; BIOFILM; CONTROLLED STUDY; DRUG EFFECT; DRUG EFFICACY; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PRIORITY JOURNAL; UROPATHOGENIC ESCHERICHIA COLI;

ANTI-BACTERIAL AGENTS; BIOFILMS; ESCHERICHIA COLI; LIPOPEPTIDES; MICROBIAL SENSITIVITY TESTS; MICROSCOPY, CONFOCAL; SURFACE-ACTIVE AGENTS;

EID: 79952818043     PISSN: 09248579     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijantimicag.2010.12.011     Document Type: Article

References (37)

1. Harrison JJ, Turner RJ, Marques LLR, Ceri H. Biofilms. Am Sci 2005;93:508-15.
2. Meyer B. Approaches to prevention, removal and killing of biofilms. Int Biodeter Biodegr 2003;51:249-53. (Pubitemid 36695767)
3. Schierholz JM, Beuth J. Implant infections: a haven for opportunistic bacteria. J Hosp Infect 2001;49:87-93. (Pubitemid 32982681)
4. O'Toole GA. Microbiology: a resistance switch. Nature 2002;416:695-6.
5. Talpur AN, Hasan AT, Sheikh MA. Intraprostatic tissue infection in catheterised patients in comparison to controls. J Pak Med Assoc 2004;54:20-4. (Pubitemid 38339126)
6. Chomarat M. Resistance of bacteria in urinary tract infections. Int J Antimicrob Agents 2000;16:483-7.
7. Wagenlehner FM, Naber KG. Hospital-acquired urinary tract infections. J Hosp Infect 2000;46:171-81.
8. Costerton JW, Stewart PS, Greenberg EP. Bacterial biofilms: a common cause of persistent infections. Science 1999;284:1318-22. (Pubitemid 29289651)
9. Nicolle LE. Empirical treatment of acute cystitis in women. Int J Antimicrob Agents 2003;22:1-6. (Pubitemid 36808713)
10. Bonmatin JM, Laprevote O, Peypoux F. Diversity among microbial cyclic lipopeptides: iturins and surfactins. Activity - structure relationships to design new bioactive agents. Comb Chem High Throughput Screen 2003;6:541-56.
11. Rivardo F, Turner RJ, Allegrone G, Ceri H, Martinotti MG. Anti-adhesion activity of two biosurfactants produced by Bacillus spp. prevents biofilm formation of human bacterial pathogens. Appl Microbiol Biotechnol 2009;83:541-53.
12. Simoes M, Pereira MO, Vieira MJ.Monitoring the effects of biocide treatment of Pseudomonas fluorescens biofilms formed under different flow regimes. Water Sci Technol 2003;47:217-23. (Pubitemid 36503146)
13. Slinger R, Chan F, Ferris W, Yeung SW, St Denis M, Gaboury I, et al. Multiple combination antibiotic susceptibility testing of nontypeable Haemophilus influenzae biofilms. Diagn Microbiol Infect Dis 2006;56:247-53. (Pubitemid 44648594)
14. Esposito S, Leone S. Antimicrobial treatment for Intensive Care Unit (ICU) infections including the role of the infectious disease specialist. Int J Antimicrob Agents 2007;29:494-500. (Pubitemid 46560365)
15. Meylheuc T, Renault M, Bellon-Fontaine MN. Adsorption of a biosurfactant on surfaces to enhance the disinfection of surfaces contaminated with Listeria monocytogenes. Int J Food Microbiol 2006;109:71-8.
16. Rivardo F, Martinotti MG, Turner RJ, Ceri H. The activity of silver against Escherichia coli biofilm is increased by a lipopeptide biosurfactant. Can J Microbiol 2010;56:272-8.
17. Irie Y, O'Toole G, Yuk MH. Pseudomonas aeruginosa rhamnolipids disperse Bordetella bronchiseptica biofilms. FEMS Microbiol Lett 2005;250:237-43. (Pubitemid 41188047)
18. O'Toole GA, Kolter R, Davey ME, Blank DH, Caiazza NC, Hogan DA. Novel compounds capable of modulating biofilms. United States Patent Application 20,020,123,077 (2002).
19. Pecci Y, Rivardo F, Martinotti MG, Allegrone G. LC/ESI-MS/MS characterisation of lipopeptide biosurfactants produced by the Bacillus licheniformis V9T14 strain. J Mass Spectrom 2010;45:772-8.
20. Harrison JJ, Stremick CA, Turner RJ, Allan ND, Olson ME, Ceri H. Microtiter susceptibility testing of microbes growing on peg lids: a miniaturized biofilm model for high-throughput screening. Nat Protoc 2010;5:1236-54.
21. Harrison JJ, Turner RJ, Ceri H. High-throughput metal susceptibility testing of microbial biofilms. BMC Microbiol 2005;5:53.
22. Harrison JJ, Ceri H, Yerly J, Stremick CA, Hu Y, Martinuzzi R, et al. The use of microscopy and three-dimensional visualization to evaluate the structure of microbial biofilms cultivated in the Calgary Biofilm Device. Biol Proced Online 2006;8:194-215.
23. Harrison JJ, Turner RJ, Joo DA, Stan MA, Chan CS, Allan ND, et al. Copper and quaternary ammonium cations exert synergistic bactericidal and antibiofilm activity against Pseudomonas aeruginosa. Antimicrob Agents Chemother 2008;52:2870-81.
24. Barry AL, Craig WA, Nadler H, Barth Reller L, Sanders CC, Swenson JM. Methods for determining bactericidal activity of antimicrobial agents; approved guidelines, vol. 19, No. 18. Document M26-A. Wayne, PA: Clinical and Laboratory Standards Institute; 1999.
25. Leonard SN, KaatzGW,Rucker LR, Rybak MJ. Synergy between gemifloxacin and trimethoprim/sulfamethoxazole against community-associated methicillinresistant Staphylococcus aureus. J Antimicrob Chemother 2008;62:1305-10.
26. Nickel JC, Ruseska I, Wright JB, Costerton JW. Tobramycin resistance of Pseudomonas aeruginosa cells growing as a biofilm on urinary catheter material. Antimicrob Agents Chemother 1985;27:619-24. (Pubitemid 15097672)
27. Ishida H, Ishida Y, Kurosaka Y, Otani T, Sato K, Kobayashi H. In vitro and in vivo activities of levofloxacin against biofilm-producing Pseudomonas aeruginosa. Antimicrob Agents Chemother 1998;42:1641-5.
28. Ceri H, Olson ME, Stremick C, Read RR, Morck D, Buret A. The Calgary Biofilm Device: new technology for rapid determination of antibiotic susceptibilities of bacterial biofilms. J Clin Microbiol 1999;37:1771-6. (Pubitemid 29235221)
29. Harrison JJ, Ceri H, Stremick CA, Turner RJ. Biofilm susceptibility to metal toxicity. Environ Microbiol 2004;6:1220-7. (Pubitemid 39606292)
30. Abdi-Ali A, Mohammadi-Mehr M, Agha Alaei Y. Bactericidal activity of various antibiotics against biofilm-producing Pseudomonas aeruginosa. Int J Antimicrob Agents 2006;27:196-200. (Pubitemid 43246948)
31. Fassi Fehri L, Wroblewski H, Blanchard A. Activities of antimicrobial peptides and synergy with enrofloxacin against Mycoplasma pulmonis. Antimicrob Agents Chemother 2007;51:468-74. (Pubitemid 46185262)
32. Tresse O, Jouenne T, Junter GA. Antibacterial efficacy of tobramycin against anaerobic Escherichia coli cultures in the presence of electron acceptors. J Antimicrob Chemother 1997;40:419-21. (Pubitemid 27437963)
33. Texter J, Ziemer P, Rhoades S, Clemans D. Bactericidal silver ion delivery into hydrophobic coatings with surfactants. J Ind Microbiol Biotechnol 2007;34:571-5. (Pubitemid 47058019)
34. Mah TF, O'Toole GA. Mechanisms of biofilm resistance to antimicrobial agents. Trends Microbiol 2001;9:34-9.
35. Carrillo C, Teruel JA, Aranda FJ, Ortiz A. Molecular mechanism of membrane permeabilization by the peptide antibiotic surfactin. Biochim Biophys Acta 2003;1611:91-7. (Pubitemid 36351436)
36. Deleu M, Paquot M, Nylander T. Fengycin interaction with lipid monolayers at the air - aqueous interface - implications for the effect of fengycin on biological membranes. J Colloid Interface Sci 2005;283:358-65. (Pubitemid 40267660)
37. Deleu M, Paquot M, Nylander T. Effect of fengycin, a lipopeptide produced by Bacillus subtilis, on model biomembranes. Biophys J 2008;94:2667-79.